Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TEDG - .35 x 39 (bird flu play)
China BioPharma (OTC:TEDG) is one of China's largest human vaccine producers.
READ THIS REPORT
http://www.theasianinvestor.com/reports/tedg.htm
TEDG - .33 x .35 (bird flu)
China BioPharma (OTC:TEDG) - is one of China's largest human vaccine producers. They already have a Influenza vaccine and are researching on H5N1 virus. They specialize in high contagious diseases like SARS, and H5N1.
TEDG price target $1.31
READ THIS REPORT
http://www.theasianinvestor.com/reports/tedg.htm
Rising Oil Prices Send Solar Stocks Up
Tuesday May 23, 3:55 pm ET
Solar Energy Stocks Climb As Oil Prices Head Higher
NEW YORK (AP) -- Shares of solar stocks soared in afternoon trading on Tuesday as investors sought refuge from soaring oil prices.
The price of light crude oil, which hit $72 on the New York Mercantile Exchange before settling to $71.76, was driven up by concerns about how Gulf Coast refineries will fare in this year's hurricane season.
As oil prices rocketed, investors turned to solar stocks, sending shares of companies such as Evergreen Solar Inc., a Marloboro, Mass.-based maker of solar power products, up 26 cents, or nearly 3 percent, to $10.70 in afternoon trading on the Nasdaq.
Shares of Evergreen may have also gotten a boost after Pacific Growth Equities analyst J. Michael Horwitz issued positive comments on the stock and reiterated his "Buy" rating.
"We remind investors that granular silicon is particularly advantageous in Evergreen Solar's proprietary String Ribbon solar module manufacturing technology. Completion of the plant is expected in late first-quarter 2008 with production expected to ramp in the third quarter of 2008," Horwitz wrote in a note.
Elsewhere in the sector, investors gobbled up other solar stocks including SunPower Corp., whose shares were up $1.46, or 5 percent, at $30.91; and shares of Energy Conversion Devices Inc. rose 72 cents to $41.32. Both stocks trade on the Nasdaq.
THPHF conf call replay
can login here to listen to a replay of todays conference call.
http://www.wallstreetnewscast.com/
move $1.30 offer...grrrrr
been a nice block of stock bought at the $1.30 offer over past several days yet that seller wont back off. Once we see that move up it could trigger strong buying.
Hey $1.30 guy (iceman)....back off the offer already. Almsot like 100,000 shares so far...or am I wrong?
MACD, RSI & Stocastic going +
Looks like GRSR MACD, RSI, and Stocastics are turning positive and may trigger some daytrading volume soon, especially if we can break $1.35 a share.
http://stockcharts.com/c-sc/sc?s=GRSR&p=D&b=5&g=0&id=t90304872105&r=66
If they can keep the news machine going and get those audits done we should be back above $2.00 pretty quickly...barring any disaster. IMO.
OT: GRSR - silicon production tech news
GiraSolar Files for Patent and Starts Certification of US Made Modules
Monday May 22, 10:42 am ET
DEVENTER, THE NETHERLANDS--(MARKET WIRE)--May 22, 2006 -- GiraSolar (Other OTC:GRSR.PK - News) today announced that it has filed for a patent on its break-through proprietary silicon production process.
http://biz.yahoo.com/iw/060522/0130642.html
silicon shortages.....
the main factor in the solar sector that i have seen is silicon. There isnt enough out there and solar firms are fighting to get any they can to fill orders. GRSR secured $30 million in silicon ingots, which means they can produce and sell up to $30 million in panels...awsome.
This patent would increase silicon production, thus decreasing the costs involved in producing panels, and thus increasing profit margins in each until produced. If this technology works the industry will be clammering to use this to increase production as demand is there.
The CEO of girasolar has alot of big connects within the solar industry, and could help get this technology out within the sector.
LETS JUST GET THOSE AUDITS DONE!!!
OT: GRSR news out
GiraSolar Files for Patent and Starts Certification of US Made Modules
Monday May 22, 10:42 am ET
DEVENTER, THE NETHERLANDS--(MARKET WIRE)--May 22, 2006 -- GiraSolar (Other OTC:GRSR.PK - News) today announced that it has filed for a patent on its break-through proprietary silicon production process.
http://biz.yahoo.com/iw/060522/0130642.html
silicon shortage solution (GRSR)
GiraSolar BV CEO Koornstra added: "This month appears to be a month in which we take some significant strides forward. The first USA made modules of our G5-36, G5-72 and G6-36 have been produced and the first steps towards UL and IEC certification have been taken. On top of that we filed our patent request for our proprietary silicon production process. These events should have a long term and strategic impact on our market position."
this could be used industry wide.
GRSR - news out
GiraSolar Files for Patent and Starts Certification of US Made Modules
Monday May 22, 10:42 am ET
DEVENTER, THE NETHERLANDS--(MARKET WIRE)--May 22, 2006 -- GiraSolar (Other OTC:GRSR.PK - News) today announced that it has filed for a patent on its break-through proprietary silicon production process.
http://biz.yahoo.com/iw/060522/0130642.html
GRSR - $65 million contract
This contract with a major European cell manufacturer represents an anticipated total revenue value of approximately $65 million for the company over the contract period which extends from Q4 2006 into Q4 2010 and should enable the group to market almost 4MWp per year extra of its own GiraSolar brand of modules. The total revenue of $65M represents yearly revenue of approximately 16.5M$ per year for a period of 4 consecutive years starting in October 2006.
http://biz.yahoo.com/iw/060316/0113520.html
Nice Solar Power Stock article
pass it along.
http://www.chicagotribune.com/business/chi-0605200311may21,1,460734.story?track=rss
what did WWAT do (financing)
They did a convertiable? Who with? Hopefully not Cornell Capital or Larus Funds.
GRSR could begin to get interesting again as they get their solar IR program ready. Just made $3.6 million last week.
Hey, see posts on RB...lol
Anyways, got an email from company and heard we may get some more updates during next week. Not many details, and rather they come out on wire, but think stuff on contracts, panels, or something. Also remeber hearing they may be presenting in some investors conference in Germany and may hear something on that.
No big breaking news but maybe that last release was a sign maybe we might see more stuff now.
Aslo, it never really dawned on me, but GiraSolar just got in $3.6 million...in the bank. Saw that mention and it hit me. These were not "oh, we made the sale...check is in the mail"...there more like sales is done and we already deposited the check in the bank. Heck, i wish i made $3.6 million this week...lol.
THAT'S BIG!
WWAT mention (solar alerts)
WorldWater & Power (OTC:WWAT) - announced the signing of contracts with homeowners in New Jersey and California to build photovoltaic solar electric systems to power their residences in parallel with their present electric utility company. The contract value of the systems in New Jersey and California is $160,540. - Last updated (05/19/06)
http://www.wallstreetnewscast.com/sectors/solar/
check this out - XSXN mention
XSunX (OTC:XSNX) - broke above their 10 day moving average today after trading down to below $1.00 in the past week. XSNX may now try to test their 20 day moving average, which is around $1.50 a share. On May 08, 2006, XSNX that the Company has begun the build out of new facilities in Golden, Colo., which, when fully configured, will house the Company's first complete product development and technology marketing facility.
http://www.wallstreetnewscast.com/sectors/solar/
dig this
GiraSolar (OTC:GRSR) - announce its subsidiary DutchSolar BV has completed a 1MWp cells supply obligation to a major German solar industry partner, and that a payment of $3 million has been received and deposited in full. The company also announced its subsidiary DutchSolar BV had completed the first supply of two containers with solar products to Spain, which represented revenue of 10% off a current $6 million contract. Total revenues = $3.6 million. chart (05/17/06)
http://www.wallstreetnewscast.com/sectors/solar/
XSNX broke 10 day MA....
might make a run up to test 20 day MA.
http://stockcharts.com/c-sc/sc?s=XSNX&p=D&b=5&g=0&id=t96182063272&r=2292
ALSO, radar GRSR....looks ready to run back up above $2.00 very soon.
http://stockcharts.com/c-sc/sc?s=GRSR&p=D&b=5&g=0&id=t30158219139&r=9123
nice buys on offer....
If GRSR can break $1.30 the MACD and stocastics will turn positive to indicate a trend upward.
Big stuff going on...hold tight.
TEDG --> $1.31 target (bird flu)
VACCINE PRODUCTION
China BioPharma's recently completed production facility is the largest and best human-vaccine production facility in China, and is also the nation's main vaccine production base whenever there is an epidemic disease outbreak within the region. Basicly, if there is an outbreak of general Influenza or the deadly Avian H5N1 Influenza (bird flu) virus, China BioPharma's vaccine production facility will be a key player in producing and distributing vaccines out to the Chinese government. The facility currently has around 140 employees. (see photo)
AVIAN H5N1 RESEARCH
China BioPharma's main focus is on vaccines for highly virulant and contagious diseases such as Ebola, SARS, and Influenza. To that effect, TEDG will be a major player in creating and mass producing a vaccine for any potential Avian Bird Flu outbreak if the need should arise in China. The company specializes in vaccines for highly contagious diseases.
PRICE TARGET OF $1.31
TEDG reported around $9 million in sales for fiscal year 2005, along with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, and only 82 million shares issued and outstanding we feel TEDG should have a fair market cap value of at least $108 million. This valuation would still only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 12 to 653 times sales.
$9 million (revenue) x 12 (price to sales) = $108 million market cap
($108 million market cap / 82 million shares outstanding = $1.31 a share)
http://www.theasianinvestor.com/reports/tedg.htm
GRSR --> $5.86 target (solar power)
Ludlow Capital Maintains A- Rating on GiraSolar (GRSR), Split Adjusts Price Target to $5.86 a Share
NEW YORK--May 03, 2006--Ludlow Capital maintained their rating on GiraSolar (OTC: GRSR) at A-, but has adjusted their 6 month price target to $5.86 a share based on a 'price to sales' ratio of 8 and their $22 million revenue projection for fiscal year 2006.
VALUATION RATING
GiraSolar announced projections of at least $22 million for fiscal year 2005/2006, which ends Sept. 2006. The average price to sales ratio within the solar sector is around 20, but for our valuation we are giving GiraSolar a price/sales ratio of only 8 for the time being. If we calculate a p/s ratio of 8 to their projected sale revenues of $22 million we come up with a market cap valuation of around $176 million.
($22 million x 8 time sales = $176 million market cap valuation)
Due to the company's recent forward split we are recalculating our valuation of GiraSolar based on current shares issued and outstanding of 30,000,000, rounded up from their 27,188,700 shares issued out currently. If you divide $176 million by 30 million shares outstanding you come out with a new price valuation target of $5.86 per share.
($176 million market cap / 30 million shares outstanding = $5.86 per share)
Thus, Ludlow Capital is maintaining its current rating on GRSR at A-, but is readjusting its 6 month price target valuation to $5.86 a share on an 8 times price to sales ratio.
http://www.ludlowcapital.com/reports/grsr.htm
China BioPharma (OTC:TEDG) - bird flu play
CHINA BIOPHARMA
China BioPharma, which owns majority rights to Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (Ebola), Influenza with high reputation, and other contagious diseases. For more information on Tianyuan Bio-pharmaceuticals visit www.ty-pharm.com
VACCINE PRODUCTION
China BioPharma's recently completed production facility is the largest and best human-vaccine production facility in China, and is also the nation's main vaccine production base whenever there is an epidemic disease outbreak within the region. Basicly, if there is an outbreak of general Influenza or the deadly Avian H5N1 Influenza (bird flu) virus, China BioPharma's vaccine production facility will be a key player in producing and distributing vaccines out to the Chinese government. The facility currently has around 140 employees. (see photo)
AVIAN H5N1 RESEARCH
China BioPharma's main focus is on vaccines for highly virulant and contagious diseases such as Ebola, SARS, and Influenza. To that effect, TEDG will be a major player in creating and mass producing a vaccine for any potential Avian Bird Flu outbreak if the need should arise in China. The company specializes in vaccines for highly contagious diseases.
PRICE TARGET OF $1.31
TEDG reported around $9 million in sales for fiscal year 2005, along with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, and only 82 million shares issued and outstanding we feel TEDG should have a fair market cap value of at least $108 million. This valuation would still only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 12 to 653 times sales.
$9 million (revenue) x 12 (price to sales) = $108 million market cap
($108 million market cap / 82 million shares outstanding = $1.31 a share)
http://www.theasianinvestor.com/reports/tedg.htm
GiraSolar (GRSR) - solar energy
In case nay new investors peek in on this board GRSR is a solar power company projecting $22 million for 2006. Ludlow Capital has a price target (conservative) of $5.80 on the stock.
CHECK IT OUT!
http://www.ludlowcapital.com/reports/grsr.htm
hey mtcinc0...thanks for passin it on
didnt get many details but new stuff on contracts revenue or something. Not many details, and actually rather they keep it to the wires, but stuff is begining to move ahead. Think we may see 2 if not 3 release over next week or so....of course we shall see as we all have heard that before. But looking good.
RHWC - I had picked up a few shares at .25 awhile back, but am looking/hoping to pick up a larger position in next couple of weeks as some cash frees up.
Yes, I too believe June will be the transition month...had thought that a month back Nothing going on now, but 2nd half should light up well on RHWC. Even if they only do a small fraction the anticipation will begin moving it up. i say RHWC breaks .30 in june, then .50 by or before early july...then its off.
TEDG ---> (read this report....hot!)
Ludlow Capital Issues $1.31 Price Target on TEDG on 'Bird Flu' Vaccine Acquisition
Research Staff
Last Update: May 19, 2006 - 7:45am EST
NEW YORK--May 19, 2006--Ludlow Capital establishes research coverage of TechEdge (OTC:TEDG), and their acquisition of China BioPharma Ltd., one of China's largest non-governmental vaccine production companies.
CHINA BIOPHARMA
China BioPharma, which owns majority rights to Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (Ebola), Influenza with high reputation, and other contagious diseases. For more information on Tianyuan Bio-pharmaceuticals visit www.ty-pharm.com
VACCINE PRODUCTION
China BioPharma's recently completed production facility is the largest and best human-vaccine production facility in China, and is also the nation's main vaccine production base whenever there is an epidemic disease outbreak within the region. Basicly, if there is an outbreak of general Influenza or the deadly Avian H5N1 Influenza (bird flu) virus, China BioPharma's vaccine production facility will be a key player in producing and distributing vaccines out to the Chinese government. The facility currently has around 140 employees. (see photo)
AVIAN H5N1 RESEARCH
China BioPharma's main focus is on vaccines for highly virulant and contagious diseases such as Ebola, SARS, and Influenza. To that effect, TEDG will be a major player in creating and mass producing a vaccine for any potential Avian Bird Flu outbreak if the need should arise in China. The company specializes in vaccines for highly contagious diseases.
PRICE TARGET OF $1.31
TEDG reported around $9 million in sales for fiscal year 2005, along with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, and only 82 million shares issued and outstanding we feel TEDG should have a fair market cap value of at least $108 million. This valuation would still only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 12 to 653 times sales.
$9 million (revenue) x 12 (price to sales) = $108 million market cap
($108 million market cap / 82 million shares outstanding = $1.31 a share)
http://www.theasianinvestor.com/reports/tedg.htm
Hey mtcinc0....
this is grock_agaon from the RB board...for some reason Im unable to post over there, grrrr. Anyways, if you could pass it on, I understand some great news is coming out probably next week on the company. Lot of the updates we've been looking for, or at least some of them...good stuff. About to get interesting.
Interesting....
I follow a few other solar stocks such as XSNX, GRSR, and STP
news out
looks like they got the other outlets to pick up their German and Spain solar news.
DEVENTER, THE NETHERLANDS, May 17, 2006 (MARKET WIRE via COMTEX) -- GiraSolar Inc. (GRSR) is pleased to announce its subsidiary DutchSolar BV has completed a 1MWp cells supply obligation to a major German solar industry partner. DutchSolar BV overachieved on its projected supply of 1MWp with 16% in surplus of its obligations. Supply had initially begun with delays in December 05 and was expected to take well into H2 of 2006. The revenue value now exceeds well over 3M$ and payments have been received in full. It is expected that DutchSolar will continue the supply of cells to German counterparts and further cooperation will be sought.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=grsr&sid=0&o_symb=grsr&f...
GRSR - solar power play (1.20 x 1.30)
With the sector price to sales ratio average around 20, GiraSolar (GRSR) should be trading at $5.86 a share on a p/s ratio of just 8....READ THIS REPORT!
http://www.ludlowcapital.com/reports/grsr.htm
H5N1 cluster in Indonesia (very serious)
A cluster of H5N1 cases found in Indonesia which WHO says is very concerning and may signal the virus may actually be jumping from human to human.
http://www.bloomberg.com/apps/news?pid=10000080&sid=aCotPF_j.uIc
keep an eye on STTK, GNBT, TEDG, NVAX, SVA, and HEB
TEDG - China's largest vaccine producer...
TEDG - .45 x .48
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
OT: TEDG - China's largest vaccine producer
With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.
http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1
China BioPharma (TEDG) - bird flu vaccine
Im surprised TEDG isnt generating more interest with what they have.
- almost $10 million in vaccine sales last year
- around $1.5 million in net income (profitable)
- CEO headed China division for Chiron Vaccines
- Board of Advisors has a number of BIG names on board
- They have a Influenza vacine in market
- Doing research on H5N1 virus
- Doing research on SARS virus
- over 140 employees & researchers
- one of China's largest non-governmental vaccine producers
TEDG - bird flu research ($1.46 target price)
Ludlow Capital Issues $1.46 Price Target on TEDG on 'Bird Flu' Vaccine Acquisition
Research Staff
Last Update: May 02, 2006 - 7:36pm EST
NEW YORK--May 02, 2006--Ludlow Capital began research coverage of TechEdge (OTC:TEDG), and their new acquisition of one of China's largest non-governmental vaccine research and production companies.
CHINA BIOPHARMA ACQUISITION
On April 10, 2006, Techedge, Inc. announced that it had acquired 100% of China BioPharma Limited, a Cayman island Company. China BioPharma, Ltd. currently holds 35% ownership rights to Tianyuan Bio-pharmaceuticals (production), and 65% of China BioPharma Development Co, Ltd. (marketing, research & business development for Tianyuan Bio-pharmaceuticals). The company currently has a number of human vaccines against Influenza, Epidemic Hemorrhagic Fever, SARS, and H5N1 Avian Bird Flu.
PRICE TARGET VALUE OF $1.46
TEDG reported around $10 million in vaccines sales last fiscal year, with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, we feel TEDG should have a fair market cap value of at least $120 million. This still would only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 17 to 1,060 times sales.
The market cap for stocks within the bird flu sector range from $72 million up to $335 million, with TEDG only having a current market cap of $35 million. We feel $120 million market cap for a Chinese vaccine biotech generating $10 million in vaccine sales, and a net profit of $1.5 million should fairly reflect a $120 million in market cap value, at least. Thus, with 82 million shares outstanding TEDG should be trading around a fair value of $1.46 a share in the open market.
($120 million market cap / 82 million outstanding = $1.46 a share)
http://www.theasianinvestor.com/reports/tedg.htm
TEDG target -----> $1.46 (bird flu)
PRICE TARGET VALUE OF $1.46
TEDG reported around $10 million in vaccines sales last fiscal year, with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, we feel TEDG should have a fair market cap value of at least $120 million. This still would only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 17 to 1,060 times sales.
The market cap for stocks within the bird flu sector range from $72 million up to $335 million, with TEDG only having a current market cap of $35 million. We feel $120 million market cap for a Chinese vaccine biotech generating $10 million in vaccine sales, and a net profit of $1.5 million should fairly reflect a $120 million in market cap value, at least. Thus, with 82 million shares outstanding TEDG should be trading around a fair value of $1.46 a share in the open market.
($120 million market cap / 82 million outstanding = $1.46 a share)
http://www.theasianinvestor.com/reports/tedg.htm
------------
RANK BY SECTOR MARKET CAP
Ranked by market caps dated May 02, 2006. NOTE: TEDG currently has one of lowest market caps at $35 million for this sector group.
AVII = $335 million
NVAX = $311 million
GNBT = $275 million
HEB = $204 million
VICL = $203 million
SVA = $169 million
STTK = $72 million
TEDG = $35 million
RANK BY PRICE/SALES RATIO
Ranked by price to sales ratio dated May 02, 2006. P/S ratio tells investors how many times sales a stock is currently trading at.
GNBT = 1,060
HEB = 192
AVII = 70
NVAX = 43
SVA = 25
VICL = 17
TEDG = 4
STTK = NA
TEDG ---> target $1.46 (bird flu vaccine)
TEDG ----> price target = $1.46
PRICE TARGET VALUE OF $1.46
TEDG reported around $10 million in vaccines sales last fiscal year, with $1.5 million in net income profit. Based on other biotech 'bird flu' plays within the sector, we feel TEDG should have a fair market cap value of at least $120 million. This still would only give TEDG a price/sales ratio of 12 as compared to others in the sector ranging from 17 to 1,060 times sales.
The market cap for stocks within the bird flu sector range from $72 million up to $335 million, with TEDG only having a current market cap of $35 million. We feel $120 million market cap for a Chinese vaccine biotech generating $10 million in vaccine sales, and a net profit of $1.5 million should fairly reflect a $120 million in market cap value, at least. Thus, with 82 million shares outstanding TEDG should be trading around a fair value of $1.46 a share in the open market.
($120 million market cap / 82 million outstanding = $1.46 a share)
http://www.theasianinvestor.com/reports/tedg.htm
------------
RANK BY SECTOR MARKET CAP
Ranked by market caps dated May 02, 2006. NOTE: TEDG currently has one of lowest market caps at $35 million for this sector group.
AVII = $335 million
NVAX = $311 million
GNBT = $275 million
HEB = $204 million
VICL = $203 million
SVA = $169 million
STTK = $72 million
TEDG = $35 million
RANK BY PRICE/SALES RATIO
Ranked by price to sales ratio dated May 02, 2006. P/S ratio tells investors how many times sales a stock is currently trading at.
GNBT = 1,060
HEB = 192
AVII = 70
NVAX = 43
SVA = 25
VICL = 17
TEDG = 4
STTK = NA
GiraSolar (GRSR) - forward split
GET IN BEFORE TUESDAY TO GET THE FORWARD SPLIT!!!
GiraSolar Announces Record Date for 5 to 2 Forward Stock Split
DEVENTER, THE NETHERLANDS, Apr 25, 2006 (MARKET WIRE via COMTEX) -- GiraSolar, Inc. (OTC: GRSR) announced today that the record date for a 5 to 2 forward split for the Company's common stock is Tuesday, May 2, 2006.
Weiland Koorstra, the President of GiraSolar, BV, commented, "Holders of the Company's common stock at the close of trading on Tuesday, May 2, 2006 will receive a 5 to 2 forward split, which we expect will then be reflected in the share price at the opening bell of Wednesday, May 03, 2006."
GRSR - 5 to 2 forward split (just out)
GiraSolar Announces Record Date for 5 to 2 Forward Stock Split
DEVENTER, THE NETHERLANDS, Apr 25, 2006 (MARKET WIRE via COMTEX) -- GiraSolar, Inc. (OTC: GRSR) announced today that the record date for a 5 to 2 forward split for the Company's common stock is Tuesday, May 2, 2006.
Weiland Koorstra, the President of GiraSolar, BV, commented, "Holders of the Company's common stock at the close of trading on Tuesday, May 2, 2006 will receive a 5 to 2 forward split, which we expect will then be reflected in the share price at the opening bell of Wednesday, May 03, 2006."
BUY 1000 SHARES NOW AND HAVE 2500 ON WED MORNING!!!
GRSR - 5 to 2 forward split (just out)
GiraSolar Announces Record Date for 5 to 2 Forward Stock Split
DEVENTER, THE NETHERLANDS, Apr 25, 2006 (MARKET WIRE via COMTEX) -- GiraSolar, Inc. (OTC: GRSR) announced today that the record date for a 5 to 2 forward split for the Company's common stock is Tuesday, May 2, 2006.
Weiland Koorstra, the President of GiraSolar, BV, commented, "Holders of the Company's common stock at the close of trading on Tuesday, May 2, 2006 will receive a 5 to 2 forward split, which we expect will then be reflected in the share price at the opening bell of Wednesday, May 03, 2006."
BUY 1000 SHARES NOW AND HAVE 2500 ON WED MORNING!!!